Machine learning approaches for survival prediction and risk-stratified treatment guidance in synchronous metastatic nasopharyngeal carcinoma: A multicenter study

机器学习方法在同步转移性鼻咽癌生存预测和风险分层治疗指导中的应用:一项多中心研究

阅读:2

Abstract

OBJECTIVE: Synchronous metastatic nasopharyngeal carcinoma (smNPC) demonstrates marked prognostic heterogeneity, which cannot be captured by conventional Cox proportional hazards (CoxPH) models owing to their limitations in managing complex, nonlinear relationships. We employed various machine learning (ML) techniques to enhance predicting overall survival (OS) in patients with smNPC. METHODS: In this multicenter retrospective study, we conducted an analysis of 404 patients diagnosed with smNPC. We developed and assessed prognostic models utilizing a traditional Cox proportional hazards model alongside six ML algorithms. The predictive performances of these models were compared using the concordance index (C-index) and time-dependent area under the curve (tAUC). Risk stratification was conducted to guide personalized treatment strategies, and Kaplan-Meier survival curve analyses were performed to evaluate the efficacy of different treatment regimens across subgroups. RESULTS: The random survival forest (RSF) model yielded the highest C-index of 0.746 and an average tAUC of 0.801 for OS, identifying RSF as the optimal predictor. Shapley additive explanations analysis revealed that five features were most influential: number of metastatic lesions, involved organs, first-line regimen, presence of liver metastasis, and using immunotherapy. Risk stratification, based on Kaplan-Meier survival curve analyses, demonstrated that local treatment of metastatic lesions significantly extended OS in low- and high-risk patient cohorts. Primary site radiotherapy conferred a survival advantage exclusively to low-risk patients, whereas immunotherapy yielded improved outcomes in high-risk patients (all p < 0.05). CONCLUSIONS: The RSF model excelled at predicting OS for patients with smNPC, providing reliable prognostic insights to guide risk-based treatment decisions in clinical practice.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。